1,3-二氯-2-(氯甲基)-5-甲氧基苯 | 59606-87-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,3-二氯-2-(氯甲基)-5-甲氧基苯
• 英文名称: 1,3-dichloro-2-(chloromethyl)-5-methoxybenzene
• 英文别名: 1,3-dichloro-2-chloromethyl-5-methoxy-benzene；2,6-Dichlor-4-methoxy-benzoylchlorid
• CAS: 59606-87-0
• 化学式: C₈H₇Cl₃O
• 分子量: 225.502
• InChiKey: DGDDTOWTALANOE-UHFFFAOYSA-N

物化性质

• 沸点：
  295.1±35.0 °C(Predicted)
• 密度：
  1.366±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,3-二氯-2-(氯甲基)-5-甲氧基苯 在 manganese(IV) oxide 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 苯 为溶剂， 反应 21.0h， 生成 2,6-二氯-4-甲氧基苯甲醛
  参考文献：
  名称：

  Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma

  摘要：

  [1,2-Bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes with one substituent in the 2-position (CH3, CF3, F, Cl, Br, I: meso- and d,l-1-PtCl2, meso-(3-5)-PtCl2, meso-(7 and 8)-PtCl2) or two substituents in the 2,6-positions (CH3, Cl: meso-2-PtCl2, meso- and d,l-6-PtCl2) in both benzene rings were synthesized and tested for estrogenic and cytotoxic activities. Two complexes (meso-6-PtCl2 and meso-7-PtCl2) possess both effects. In comparative tests on estrogen receptor positive and negative mammary tumors in cell culture (MCF 7, ER+ and MDA-MB 231, ER-) and in animals (MXT, ER+ and MXT, ER-, mouse), meso-6-PtCl2 shows a selective effect on the estrogen receptor positive mammary carcinoma. A further increase of efficacy was achieved with the water-soluble (sulfato)platinum(II) derivative (meso-6-PtSO4). On the DMBA-induced hormone dependent mammary carcinoma of the SD rat, meso-6-PtSO4 is significantly more active than its ligand (meso-6) and cisplatin.

  DOI：

  10.1021/jm00396a012
• 作为产物：
  描述：

  聚合甲醛 、 3,5-二氯苯甲醚 在 盐酸 、 硫酸 作用下， 反应 7.0h， 生成 1,3-二氯-2-(氯甲基)-5-甲氧基苯
  参考文献：
  名称：

  Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma

  摘要：

  [1,2-Bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes with one substituent in the 2-position (CH3, CF3, F, Cl, Br, I: meso- and d,l-1-PtCl2, meso-(3-5)-PtCl2, meso-(7 and 8)-PtCl2) or two substituents in the 2,6-positions (CH3, Cl: meso-2-PtCl2, meso- and d,l-6-PtCl2) in both benzene rings were synthesized and tested for estrogenic and cytotoxic activities. Two complexes (meso-6-PtCl2 and meso-7-PtCl2) possess both effects. In comparative tests on estrogen receptor positive and negative mammary tumors in cell culture (MCF 7, ER+ and MDA-MB 231, ER-) and in animals (MXT, ER+ and MXT, ER-, mouse), meso-6-PtCl2 shows a selective effect on the estrogen receptor positive mammary carcinoma. A further increase of efficacy was achieved with the water-soluble (sulfato)platinum(II) derivative (meso-6-PtSO4). On the DMBA-induced hormone dependent mammary carcinoma of the SD rat, meso-6-PtSO4 is significantly more active than its ligand (meso-6) and cisplatin.

  DOI：

  10.1021/jm00396a012

文献信息

• Synthesis of Novel Structurally Simplified Estrogen Analogues with Electron-Donating Groups in Ring A
  作者：Lutz Tietze、Carsten Vock、Ilga Krimmelbein、Linda Nacke

  DOI：10.1055/s-0029-1216810

  日期：2009.6

  A library of 25 novel estrogen analogues were prepared in five to eight steps from mostly commercially available substituted anisoles via bromination, formylation, Corey-Fuchs reaction, elimination, and Sonogashira reaction.

  合成了一系列25种新型雌激素类似物，这些化合物通过五个至八个步骤，主要以市售的取代茴香醚为原料，经过溴化、甲醛化、Corey-Fuchs反应、消除反应及Sonogashira反应制备得到。
• Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
  申请人：Neurogen Corporation

  公开号：US06372743B1

  公开（公告）日：2002-04-16

  Disclosed are compounds of the formula: where R1, R2, R3, R4, R5, R6, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.

  揭示了以下化合物的结构：其中R1、R2、R3、R4、R5、R6和X的定义如下。这些化合物是NPY1受体的选择性调节剂。这些化合物在治疗多种中枢神经系统疾病、代谢性疾病和外周疾病方面具有用途，尤其是在治疗进食障碍和高血压方面。还提供了治疗此类疾病的方法以及包装的药物组合。发明的化合物还可用作NPY1受体定位的探针和NPY1受体结合测定中的标准。给出了使用这些化合物进行受体定位研究的方法。
• Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines
  申请人：Neurogen Corporation

  公开号：US20030069246A1

  公开（公告）日：2003-04-10

  Disclosed are compounds of the formula: 1 where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.

  本发明揭示了以下化合物的公式：1其中R1、R2、R3、R4、R5、R6和X在此定义。这些化合物是NPY1受体的选择性调节剂。这些化合物在治疗许多中枢神经系统疾病、代谢性疾病和外周疾病，特别是进食障碍和高血压方面非常有用。本发明还提供了治疗这些疾病的方法以及包装的制药组合物。本发明的化合物还可用作NPY1受体定位的探针，以及在NPY1受体结合测定中的标准。给出了在受体定位研究中使用这些化合物的方法。
• Prophylactic/Therapeutic Agent for Diabetes
  申请人：Cho Nobuo

  公开号：US20090264650A1

  公开（公告）日：2009-10-22

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种11β-羟基类固醇脱氢酶1抑制剂，其包括由式（1）表示的化合物，其中每个符号如描述中所定义的，或其盐或前药。本发明的11β-羟基类固醇脱氢酶1抑制剂具有优异的活性，可用作药物剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖症、异常脂质代谢、高血压等的药剂。
• PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1864971A1

  公开（公告）日：2007-12-12

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种 11β-羟基类固醇脱氢酶 1 抑制剂，由式（1）代表的化合物组成： 其中各符号如说明中所定义，或其盐，或其原药。本发明的11β-羟类固醇脱氢酶1抑制剂具有优异的活性，可作为药物制剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖、脂代谢异常、高血压等疾病的药物。